TriangleBevacizumab (NCT07446322)
Bevacizumab trial for Ras-mutated Metastatic Colorectal Cancer (NCT07446322). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with RAS-mutated, microsatellite-stable metastatic colorectal cancer after first-line oxaliplatin progression or intolerance, or relapse within six months of adjuvant oxaliplatin. Curative surgery or radiation must be unsuitable; prior irinotecan is excluded.
The idea: compare FOLFIRI chemotherapy plus bevacizumab with or without intravenous pelareorep. Pelareorep is a virus intended to replicate in cancer cells with activated RAS signaling and stimulate immune attack. Bevacizumab blocks tumor blood-vessel growth. Researchers measure tumor response and safety.
This phase 2 study plans 60 patients. Oncolytics Biotech sponsors 19 recruiting US locations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.